Physician profile
Nirupama Vemuri
NPI 1659303980
$8,772.75
in general payments reported to CMS, 2019-2025
47 companies · $977 in 2025
The $977 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $1,288 · 2021: $2,195 · 2022: $1,315 · 2023: $1,360 · 2024: $774 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,885 · Consulting Fee: $175 · Education: $50.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,884.98 |
| Consulting Fee | $175.00 |
| Education | $50.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,453.09 | 2019-2025 | Breztri, Farxiga, Lokelma |
| Novo Nordisk INC | $1,308.01 | 2019-2025 | Wegovy |
| Amgen INC. | $602.67 | 2019-2025 | Prolia, Repatha, Otezla |
| Lilly USA, LLC | $564.63 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $484.52 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.47 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $409.65 | 2019-2025 | Arexvy, Trelegy Ellipta, Jesduvroq |
| Vifor Pharma, INC. | $294.93 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $288.20 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $262.52 | 2020-2024 | Acthar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $231.67 | 2022 | |
| Abbott Laboratories | $219.46 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $218.90 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $216.51 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $200.65 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirupama Vemuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.